Progesterone subcutaneous - IBSA

Drug Profile

Progesterone subcutaneous - IBSA

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator IBSA
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Premenstrual syndrome; Spontaneous abortion

Most Recent Events

  • 11 Nov 2016 IBSA plans a phase III trial for Premenstrual syndrome in Italy (SC) in 2017 (NCT02950948)
  • 10 Nov 2016 IBSA plans a phase III trial for Spontaneous abortion in Italy (SC) (NCT02950935)
  • 27 Oct 2016 Clinical trials in Premenstrual syndrome in Italy before October 2016 (SC) (NCT02950948)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top